• Prunin Targets Senecavirus A IRES-Driven Replication

  2026-09-03

  The reference study identifies prunin as an inhibitor of Senecavirus A replication in cell-based and animal models, with evidence implicating the viral internal ribosome entry site (IRES). Its main contribution is to connect antiviral activity with a translation-control mechanism rather than describing only a reduction in viral burden, while also highlighting the need for cleaner mechanistic assays in RNA-virus research.

• Clathrin-Mediated Entry of Type III GCRV

  2026-09-02

  Wang et al. used pharmacological inhibition, transmission electron microscopy, and real-time quantitative PCR to define how genotype III grass carp reovirus enters CIK cells. Their results identify a dynamin-dependent, clathrin-mediated, endosomal acidification-sensitive route and show how Dynasore can help separate viral entry mechanisms from broader replication effects.

• Plant Cell Lysis Buffer for WB and IP

  2026-09-02

  Plant Cell Lysis Buffer for WB and IP is a non-denaturing extraction reagent for preparing plant proteins for Western blotting, immunoprecipitation, co-immunoprecipitation, PAGE, and ELISA. Its 1% Triton X-100 formulation combines protease and phosphatase inhibitors to support protein integrity and native interaction studies.

• Cytochalasin B: Actin Assay Workflows

  2026-09-01

  Cytochalasin B (NSC 107658) offers a reversible way to perturb actin-dependent uptake, migration, cytokinesis, and pathogen entry. This practical guide connects mechanism to dose-finding, S2-cell infection assays, orthogonal controls, and troubleshooting that separates actin target engagement from generalized toxicity.

• Structure-Guided Proteomimetics for SARS-CoV-2

  2026-09-01

  This study converts two hACE2 recognition elements into constrained peptide mimetics and links them to preserve the three-dimensional geometry of the SARS-CoV-2 S-RBD/hACE2 interface. The lead proteomimetic selectively disrupted this interaction, inhibited pseudovirus entry, and showed epithelial stability and permeability properties relevant to further intranasal delivery research.

• Natural Compounds Against SARS-CoV-2: Docking Evidence

  2026-08-31

  This 2022 Journal of Molecular Modeling study used virtual screening, molecular docking, and molecular dynamics to evaluate vitamins as potential inhibitors of SARS-CoV-2 entry and replication. Its main contribution is a structure-based comparison of compounds targeting both the spike receptor-binding domain and 3CL protease, while its computational predictions require biochemical and cellular validation.

• OMV-Displayed mRNA Antigens for Tumor Vaccines

  2026-08-30

  This study developed genetically engineered bacterial outer membrane vesicles that rapidly bind sequence-labeled mRNA and promote antigen delivery to dendritic cells. The platform combined L7Ae-mediated RNA capture with listeriolysin O-dependent endosomal escape, producing tumor control, complete regression in a subset of treated mice, and durable immune memory.

• JNJ-10198409: From PDGF Mechanism to Translation

  2026-08-29

  A translational framework for using JNJ-10198409 to connect PDGF-BB receptor engagement with reproducible proliferation, angiogenesis, oncology, and fibrosis research outcomes.

• Cancer Drug Response Assays: Arrest Versus Death

  2026-08-29

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated measures capture different relationships between growth inhibition and cell death. The framework supports more informative in vitro cancer research by pairing endpoint measurements with temporal and mechanistic interpretation.

• Purmorphamine: Smoothened Agonist Research Guide

  2026-08-28

  Purmorphamine is a synthetic Smoothened agonist used to activate Hedgehog signaling in osteogenic, neural, and sensory research. Product benchmarks report approximately 1 μM EC50 for alkaline phosphatase induction and approximately 1.5 μM IC50 for competitive BODIPY-cyclopamine binding.

• Z-VAD-FMK in Oncolytic Cancer Research

  2026-08-28

  Z-VAD-FMK is more than a pan-caspase inhibitor: it can function as a causal perturbation for interpreting apoptosis during oncolytic virus treatment. This guide connects inhibitor-based assay design with breast cancer findings from rMeV-Hu191 research.

• Azilsartan (TAK-536): AT1 Signaling Research Guide

  2026-08-27

  Azilsartan, also known as TAK-536, is a selective AT1 receptor inverse agonist used to interrogate angiotensin II signaling. Its reported IC50 is 2.6 nM, and a 2024 astrocyte–microglia study used azilsartan to examine AT1-linked changes in reactive astrocyte markers.

• Dimethyloxalylglycine (DMOG) Protocol Guide

  2026-08-27

  Dimethyloxalylglycine (DMOG), SKU A4506, provides a cell-permeable chemical approach for studying hypoxia-inducible factor stabilization and oxygen-sensing responses under controlled laboratory conditions. It is intended for scientific research, including cell-based hypoxia and inflammation studies, and should not be used as a diagnostic, therapeutic, or validated clinical dosing product.

• Doxorubicin and SMYD2: A Smarter Resistance Strategy

  2026-08-26

  Doxorubicin is more than a cytotoxic benchmark: paired with SMYD2 biology, it becomes a strategic probe of DNA damage, epigenetic state, and multidrug resistance. This translational framework connects Adriamycin mechanism with actionable experimental design in renal cell carcinoma and broader oncology research.

• Matrine: From Cell Death to Assay Design

  2026-08-26

  Matrine, also indexed as Sophocarpidine, is a multifunctional Sophora alkaloid with emerging activity against tumor stemness, apoptosis, and inflammation. This article translates recent thymoma findings into an evidence-aware assay strategy while distinguishing validated observations from mechanistic hypotheses.

454 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page